Bio-Rad Laboratories Inc (BIO)

Investment Committee Summary

Investment Thesis

Bio-Rad develops and manufactures instruments, consumables and software for life-science research and clinical diagnostics. The economics are the classic instrument model: place a platform once, then earn recurring revenue from the reagents and consumables that run only on it. That installed base is the durable asset, and it is also why growth is slow — placements are budget-dependent, and the recurring stream grows with the base rather than ahead of it. An operating margin near 11% is unremarkable for the category and points to a cost base carrying more than current revenue supports. At $380 the shares trade at about 43x forward earnings and are trading rich to the triangulated value (-33%), against a twelve-month base target of $299; the quote also sits above the 52-week high on file, so the recorded range is stale. The deciding variable is academic, government and biopharma research funding, which sets instrument placements and therefore the future consumable stream. The company carries net debt of ~$0.9B. The most damaging risk is paying a high multiple for slow, funding-dependent growth on a margin that has not yet proved it can expand.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($380) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear case is a funding-led placement freeze at a demanding multiple. Instrument purchases are among the first items cut when research budgets tighten, because they are capital goods with a deferrable replacement cycle — and every deferred placement is a permanent reduction in the future consumable annuity, not a timing effect. On an operating margin near 11%, a modest revenue decline removes a large share of profit, since manufacturing and field-service infrastructure is fixed. The valuation is the greater exposure: a high multiple on a low-margin, slow-growth scientific-industrial business is a bet on margin expansion, and if that expansion is deferred again the multiple compresses toward the category norm regardless of what revenue does. Diagnostics competition adds price pressure on the consumable side, where the annuity is supposed to be safest. The structural scenario holds a fifth of the weight with a target below the 52-week low, and with the shares above the triangulated value there is no margin of safety in the entry price.

Key Debate

Gross Margin explains 64% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 40.1× consensus forward EPS, vs the house DCF terminal 29.0×, and a peer median 31.9×. The house DCF sits 42% below spot, so the market is pricing in more than the house case — roughly 5.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($132) to a 'Bull — Re-Rate' bull case ($529); the probability-weighted blend (PWEV $299) is -21% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 2.2% of revenue; free cash flow net of SBC is $0.32B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $132). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $223). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $310). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $419). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $529). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $263 and 26% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (64% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 29.0x terminal FCF multiple → $222. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $500; the peer-median forward P/E is 31.9x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 93% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Life-Science Tools, Services & Software multiple (AI re-rating) (base 34.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 31.5× (simple median 31.9×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $237–$390, centre $304 (-20% vs spot); spot sits at the 93rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $529.

Company Overview & Business Model

Bio-Rad Laboratories Inc — HEALTHCARE · MEDICAL DEVICES. Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.

How it makes money.

Edge. Narrow moat — inferred from a 11% operating margin and the Life-Science tools & services business model. Some pricing power / share stability; terminal multiple near the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Devices Tools

This name sits in the Health Care — Devices Tools cluster as a Life-Science tools, services & software name. biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: ILMN (Life-Science tools, services & software) · MEDP (Life-Science tools, services & software) · PEN (medical devices & equipment) · GMED (medical devices & equipment) · BRKR (medical devices & equipment) · BIO (Life-Science tools, services & software) · AVTR (Life-Science tools, services & software) · LNTH (medical devices & equipment) · LIVN (medical devices & equipment) · NVST (medical devices & equipment) · DOCS (Life-Science tools, services & software) · HAE (medical devices & equipment) · XRAY (medical devices & equipment)

Mapping note: name-level 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) + 'R&D-Spend Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — Bioprocessing / Biologics Recovery' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Devices Tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 70% — earnings not cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.11 vs analyst floor +0.00 → delta +0.11 (n=25 mgmt / 15 Q&A; 2nd pctile across the S&P book, z -1.9).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 70 articles): avg ticker sentiment +0.04 (bullish 13% / bearish 7%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +22.5%.
• Prior-forecast backtest (19 snapshots, 2026-07-21→2026-09-03): directional hit-rate 10%; mean predicted -14.2% vs realised +9.1%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

4 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 2 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 2.65 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 380.12 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $380; 52-week range $237–$390; engine rating SELL; house target $299 (-21%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $256 (-33% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

60.0/100 (confidence band 49.6–70.4), 59th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 60.0 → 59.9 → 59.9 → 60.1 → 59.6 → 59.6 → 59.9 → 59.9.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $298.86.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.37, vs QQQ +0.28 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Collar. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with rich premium — finance downside protection by selling an expensive call (collar)
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 77th percentile of the cross-section → high vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 29th percentile of its own month-end history (decile 3). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +6.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +6.9pp): 38-DTE 32% · 101-DTE 36% · 255-DTE 39%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 31.7% (elevated regime) · expected move ±8.0% (2026-10-16) · put/call OI 0.47 · ATM Δ 0.54 / Θ -0.22 / ν 0.49. Direction: SHORT/HEDGE (implied return -32.7% to triangulated fair value $255.72).

Bear Put Spread (Bearish) — Long 380 P / Short 270 P · 2027-03-19 · net debit $29.45 · max profit $80.55 · breakeven $350.55 · RoR 274.0% · max loss $29.45 · priced from the listed chain (EOD marks)

Defined-risk downside expression: the debit caps the loss, with the position gaining as the stock falls toward the lower strike — a way to act on a bearish view without shorting stock. Illustrative — no outcome is implied or guaranteed.

Protective Put (if held) (Hedge) — Long 380 P · 2027-03-19 · premium $35.25 · floor 0.0% · max loss $35.25 · priced from the listed chain (EOD marks)

Insurance for an existing holding — a known premium buys a floor while leaving the upside intact. A way to hold through a binary event or volatility with defined downside.

Protective Collar (if held) (Hedge) — Long 340 P / Short 420 C · 2027-03-19 · net $8.4 · floor -11.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling. Elevated implied volatility currently enriches the premium collected.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -21% vs spot
• Monte Carlo median implies -31% vs spot
• DCF fair value implies -42% vs spot — but this is terminal-value sensitive (exit-multiple $222 vs Gordon $134, 40% apart), so it carries less weight
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -65% vs spot
• Net: the valuation anchor itself sits 32.7% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $6B = EV $7B; − net debt $0.9B → equity $6B ÷ diluted shares $0.03B = $222/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $134/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 9% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $500 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (139.0); Terminal × ±15% (64.0); Revenue CAGR ±3pp (53.0); Capex intensity ±15% (42.0); WACC ±1pp (22.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 29×, FY+5 revenue $3B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.